Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma

Learn more:

• clinicaltrials.gov: #NCT03927105
• See Study Locations on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.